U ncertainty persists over the bene ts of populationbased screening for hereditary haemochromatosis, in spite of the fact that many features of this disorder satisfy the usual criteria for such screening.
In its fully expressed clinical form, haemochromatosis is associated with serious morbidity and mortality. The varied clinical manifestations are a consequence of excess iron deposition in tissue ("iron overload"), which results in damage to organs such as the liver, heart and pancreas. This damage can be avoided by the simple remedy of periodically removing blood and therefore the excess iron. A readily available biochemical test can be used in serum to detect the presence of excess iron.
Approximately 90% of individuals with clinically de ned haemochromatosis are homozygous for the C282Y mutation on the HFE gene, and this genotype is present in about ve per 1000 individuals of northern European origin.
1,2 The case for screening looks persuasive, but there is a problem. In the general population there is a discrepancy between the frequency of the homozygous genotype and the apparent frequency of serious clinical manifestations due to iron overload. 2, 3 This discrepancy has not been explained. It has been variously attributed to under-diagnosis of the disorder or incomplete penetrance, or both. The present analysis focuses on one measurable endpoint of haemochromatosis, hepatocellular carcinoma, as a step towards better understanding the health consequences of this disorder in males.
The liver is the primary target organ for excess iron deposition. Even before recognisable symptoms of iron overload appear, brosis can be visible histologically in biopsy specimens.
2,4,5 As iron deposition progresses, cirrhotic changes appear and some individuals with cirrhosis develop liver cancer. Any strategy that prevented hepatocellular carcinoma arising from this cause would also incidentally prevent many, if not all, serious clinical manifestations in other target organs.
METHODS
The purpose of this analysis was to demonstrate how to estimate the number of cases of hepatocellular carcinoma that might occur over the lifetime of a cohort of 1,000,000 white males, aged 30-34 years, and how many of these might be attributable to hereditary haemochromatosis. Four sources were used for this purpose:
(1) the US 1999 life table for white males; 6 (2) the age-speci c yearly incidence rates by ve-year age group of hepatocellular carcinoma for non-Hispanic Caucasian males in California; The analysis was limited to males because they develop serious clinical manifestations of haemochromatosis at a considerably higher rate than females, even though the inheritance pattern is autosomal recessive. This is thought to be due to the protective effect of blood loss through menstruation and childbirth.
Objectives: Homozygosity for the C282Y mutation of the HFE gene is the main cause of iron overload in hereditary haemochromatosis. This study calculated the number of hepatocellular carcinoma cases among a cohort of white males that could be attributed to C282Y homozygosity. A better understanding of the extent of potentially preventable mortality arising from this cancer might help with decision making about the feasibility of population screening.
Methods:
We combined information from published life tables, age-speci c cancer rates and DNA studies of archived liver biopsy specimens to calculate the number of cases of hepatocellular carcinoma that might occur during the lifetime of a cohort of 1,000,000 men, including a subgroup of 5000 C282Y homozygotes.
Results: Hepatocellular carcinoma was estimated to occur in 2673 men in the cohort (1:374); 267 of these cases were in the subgroup of 5000 C282Y homozygotes (1:17). If these 267 cases were prevented, the remaining lifetime risk among all males would be 1:416. The relative risk for this cancer in C282Y homozygotes is 23.
Conclusions:
There continues to be uncertainty about the ef cacy of screening for haemochromatosis.
Hepatocellular carcinoma is the most readily quanti able serious health problem attributable to this source. Further con rmatory DNA (C282Y) studies would be helpful in larger, unbiased sets of archived biopsy specimens, as a way to con rm the present estimate. Any strategy designed to prevent attributable liver cancer is likely to prevent other serious problems from haemochromatosis as well. Table 1 shows the number of men expected to remain alive in each ve-year period in the cohort, and the number who are homozygous for the C282Y mutation in each time period (5 per 1000 of those remaining alive). No attempt is made to account for excess losses of C282Y homozygotes because this adjustment would have a negligible in uence on the nal calculations. The age-speci c incidence rates of hepatocellular carcinoma increase substantially with age. The total number of cases in each ve-year period is determined by multiplying the average yearly incidence rate by the average number of living males, and then multiplying that gure by ve. The nal column lists the estimated number of hepatocellular carcinoma cases attributable to hereditary haemochromatosis (de ned by C282Y homozygosity) in each age group. This nal column is derived by multiplying the total number of cases that occur in a given age group by a constant proportion (10%). This proportion is derived from the published archived biopsy study. 8 It is possible that the contribution of hereditary haemochromatosis to the cases of hepatocellular carcinoma might be less in the earlier years and relatively more in the later years, but available data are too sparse to make assumptions of this type.
RESULTS
Overall, 267 of the 2673 hepatocellular carcinoma cases (10%) that occur over the lifetime of this cohort are attributable to hereditary haemochromatosis and, hence, are potentially preventable. The average age of occurrence is approximately 70 years. About one in 19 C282Y homozygous males (267:5000-267, or 1:18) will develop hepatocellular carcinoma attributable to iron overload during their lifetime (in the absence of preventive treatment). If treatment were completely effective and all of these carcinomas were to be prevented, the remaining lifetime risk among all males would be 1:416 (2673-267:1,000,000-[2673-267]). C282Y homozygote males thus have a relative risk of about 23 (416/18) for this type of cancer. This is consistent with an estimated 23-fold increased risk that was calculated using multiple-cause mortality les compiled by the National Center for Health Statistics for the years 1979 to 1992. 9 Those les allowed diagnoses of liver cancer to be tallied according to whether or not haemochromatosis was also reported to be present.
DISCUSSION
This analysis shows that about 53 (267/5) per 1000 C282Y homozygous white males in California might be expected to develop hepatocellular cancer attributable to iron overload during their lifetime in the absence of treatment, compared with the background rate of about two or three per 1000 men. Critical data in our analysis come from the archived biopsy study of liver cancer, from a population base of 500,000, by Willis and his associates. 8 In that study, samples were available for C282Y genotyping in 28 of 49 hepatocellular carcinomas, six of 22 other primary liver cancers and 190 of 360 cases of cirrhosis that had been biopsied over a 20-year period. Homozygosity for the C282Y mutation was present in three of the 24 hepatocellular carcinoma specimens from males (12.5%, 95% con dence interval 2.7% to 32%). A lower gure of 10% is used in the calculations in Table 1 in order to account for the possibility that a small proportion of hepatocellular carcinoma cases in this group are not attributable to iron overload.
Willis and his associates estimated that 130 males with C282Y homozygosity would be included in the 20-year period covered by their retrospective analysis. Three of those males (odds 1:42) developed hepatocellular carcinoma during that time. In the present analysis, substituting agespeci c UK incidence rates for those in California 7 would yield a lifetime rate of one case of hepatocellular carcinoma for every 28 homozygous males, which is in reasonable agreement with the estimates of Willis and his associates. When making estimates of this type, it is important to take into account variations in hepatocellular carcinoma rates between countries, as well as limiting analyses to males in racial/ethnic groups with a relatively high frequency of the C282Y mutation. For example, a study on liver biopsy material from Italy found no C282Y homozygotes among 63 males with hepatocellular carcinoma. 10 Given the low frequency of this mutation in that region of Italy, this nding is consistent with expectation. The effect of variations in population-level exposures to other agents, such as alcohol and hepatitis viruses, on the relative frequency of C282Y-related hepatocellular carcinoma is more dif cult to determine. One study has documented a synergistic effect between alcohol and C282Y homozygosity for the induction of cirrhosis, 11 and the same may be true for other toxic agents.
Although con dence intervals are broad for Willis's data, the estimates provide a useful starting point for calculations. This also points the way for other investigators to carry out similar DNA studies on archived biopsy specimens. If studies of this type from other countries con rm Willis's results, it would be possible to make decisions more con dently about whether to develop screening strategies. One similar study, ,800  4960  21  2  40-44  980,500  4900  40  4  45-49  964,200  4820  62  6  50-54  940,500  4700  136  13  55-59  905,300  4530  272  27  60-64  851,900  4260  362  36  65-69  773,600  3870  450  45  70-74  664,600  3320  388  39  75-79  527,500  2640  510  51  80-84  366,900  1830  261  26  85-89  202,900  1015  115  12  90-94  80,500  400  45  5  95-99  20,300  100  11  1   Totals  2673  267 in France, which was limited to cases of hepatocellular carcinoma in the absence of cirrhosis, found two C282Y homozygotes among 33 affected males. 12 There is no question that other serious problems, such as cirrhosis, adult-onset insulin-dependent diabetes and cardiomyopathy are also important sources of morbidity. Some of these will occur more often than hepatocellular carcinoma. They are not, however, as accessible to the kind of quantitative endpoint analysis performed in the present study. It is unlikely that future screening trials will add further insight about morbidity and mortality. Archived biopsy studies may be the most useful source for deriving this information.
The present analysis helps to put in perspective two recent screening trials, one in California and a second in Norway. These reported little evidence of morbidity among men found to be C282Y homozygotes. The California study included 14,577 men, 73 of whom (one in 200) were homozygous for the C282Y genotype.
2 Two major ndings emerged. First, the symptoms commonly associated with haemochromatosis did not occur more often among C282Y homozygotes, although elevated liver enzymes and a history of liver problems were more frequent (liver biopsies were obtained from only a few). Second, the observed age distribution of homozygous men was slightly displaced toward younger ages than expected. This did not reach statistical signi cance (probably because there were too few study subjects) but it was consistent with a slight excess of deaths. Based on the present analysis, 39 cases of hepatocellular carcinoma would be expected during the lifetime of the 14,577 males in the California study, and four of these might be attributable to iron overload due to C282Y homozygosity. In a cross-sectional study of relatively healthy individuals such as that reported, it is not surprising that the four expected cases were not identi ed. Few liver biopsies were performed and so the frequency of brosis and cirrhosis could not be determined.
The second trial was carried out in a county in Norway between 1995 and 1997. 5 Overall, 65,238 subjects (30,579 men) were studied. According to a separate study of genotype frequency in Norway, 13 an estimated 183 C282Y homozygous men ought to have been present. Genotyping was performed only on study subjects with elevated transferrin saturation measurements. Among men, 195 C282Y homozygotes could be accounted for by elevated transferrin saturation measurements (171 newly genotyped cases, six previously diagnosed and 18 estimated among drop-outs). This was slightly more than expected, which indicates a high level of ascertainment. Liver biopsy was performed on 129 of 158 men with both elevated transferrin saturation and serum ferritin levels; some of these were not homozygous for the C282Y mutation. Fibrosis was identi ed in 11 men and cirrhosis in four (four of the men with brosis also had cirrhosis). Fibrosis without cirrhosis among homozygous males was thus about 4-6% and about 2-3% among those with cirrhosis. Once again, the cross-sectional nature of this study limits expectations of the extent of liver pathology which might be detected. Over the lifetime of these 30,579 men, 82 cases of hepatocellular carcinoma might be expected, about eight of which might be attributable to C282Y homozygosity.
To our knowledge, this is the rst time that an attempt has been made to estimate the lifetime number of hepatocellular carcinoma cases attributable to hereditary haemochromatosis in males. These cases are potentially preventable. If larger studies con rm the present estimates, a decision may be made that a preventive effort is worthwhile. The question then becomes which screening strategy would be the most effective. Males of northern European origin, best represented in the US by the de nition "non-Hispanic Caucasians", are the group with the highest rate of C282Y homozygosity and a predisposition to develop clinical manifestations. This means that any prevention strategy would, most logically, begin with this group.
